Delivery Order SPE2DB22D2211-SPE2DB24FMSJ1
- Not listed
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. The contract has a ceiling value of $32,788.78 and an ultimate completion date of April 26, 2024. The contract is a Firm Fixed Price Delivery Order, and there is no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- This federal contract award is for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml pen (2 ml) to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. (doing business as Amerisourcebergen). The contract, valued at $21,110.88, is a delivery order with a firm fixed price, and it has an ultimate completion date of February 28, 2023. Amerisourcebergen...
- This federal contract award is for the delivery of Dupixent 200 mg/1.14 ml pens to the U.S. government. The award was issued to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $8,236.04 and an ultimate completion date of October 19, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The award, with a ceiling value of $5,005.47, is for the delivery of Dupixent 300 mg/2 ml pen, a pharmaceutical product. The contract has an ultimate completion date of April 29, 2024 and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen 2 ml pharmaceutical products. The contract was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $12,109.75 and is a firm fixed-price delivery order with a completion date of November 8, 2023. The contract is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a significant...
- This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,805.87 firm fixed price delivery order contract has a completion date of May 2, 2024 and was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a $999,999,999...
- This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen injectors to support Defense Logistics Agency (DLA) requirements. The $61,023.47 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of May 10, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml pens. The $25,339.82 firm-fixed-price contract has an ultimate completion date of August 19, 2022. Amerisourcebergen is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of...
- The federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, 2 ml, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,834.82 firm fixed-price delivery order contract has a completion date of November 29, 2023 and is not designated as a set-aside requirement. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- The federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen 2 ml, awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract has a total ceiling value of $22,336.77 and is a firm fixed-price delivery order. There was no set-aside designation for this award. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB24FMSJ1Delivery Order
This federal contract award is for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml pen (2 ml) to the Defense Logistics Agency (DLA), a component of the Department of Defense. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $18,381.23 and a completion date of January 31, 2024. It is a firm fixed-price delivery order contract, without any set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs. The company also maintains a smaller IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.4k | 1/30/24 |